A statistical method for estimating the no-observed-adverse-event-level
Applications
2021-01-05 v1
Abstract
In toxicological risk assessment the benchmark dose (BMD) is recommended instead of the no-observed-adverse effect-level (NOAEL). Still a simple test procedure to estimate NOAEL is proposed here, explaining its advantages and disadvantages. Versatile applicability is illustrated using four different data examples of selected in vivo toxicity bioassays.
Cite
@article{arxiv.2101.00427,
title = {A statistical method for estimating the no-observed-adverse-event-level},
author = {Ludwig A. Hothorn},
journal= {arXiv preprint arXiv:2101.00427},
year = {2021}
}
Comments
4 data examples, with raw data and R-code